幽门螺杆菌
奥美拉唑
抗菌剂
微生物学
细菌
抗生素
质子抑制剂泵
体内
抗药性
抗生素耐药性
生物
抗菌剂
化学
药理学
生物化学
生物技术
遗传学
作者
Qian Tong,Chengqiang Yin,Xudong Hang,Yuefan Bai,Chongwen Zhang,Jin Xu,Yan Huang,Yixin Ge,Tianyu Chen,Liping Zeng,Jia Jia,Hongkai Bi
摘要
ABSTRACT Currently, Helicobacter pylori eradication by antibiotic therapy faces various challenges, including antibiotic resistance, side effects on intestinal commensal bacteria, and patient compliance. In this study, loureirin A (LrA), a traditional Chinese medicine monomer extracted from Sanguis Draconis flavones, was found to possess specific antibacterial activity against H. pylori without the bacteria displaying a tendency to develop resistance in vitro . LrA demonstrated a synergistic or additive effect when combined with omeprazole (a proton pump inhibitor) against H. pylori . The combination of LrA and omeprazole showed promising anti- H . pylori potential, exhibiting notable in vivo efficacy comparable to standard triple therapy in mouse models infected with both drug-sensitive and drug-resistant H. pylori strains. Moreover, the narrow-spectrum antibacterial profile of LrA is reflected in its minimal effect on the diversity and composition of the mouse gut microbiota. The underlying mechanism of action of LrA against H. pylori involves the generation of bactericidal levels of reactive oxygen species, resulting in apoptosis-like cell death. These findings indicate that LrA is a promising lead compound targeting H. pylori without harming the commensal bacteria.
科研通智能强力驱动
Strongly Powered by AbleSci AI